<DOC>
	<DOCNO>NCT01077518</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy ofatumumab bendamustine combination therapy patient indolent B-cell NHL respond rituximab rituximab-containing regimen within 6 month last rituximab treatment .</brief_summary>
	<brief_title>Ofatumumab Bendamustine Combination Therapy Compared With Bendamustine Monotherapy Indolent B-cell Non-Hodgkin 's Lymphoma ( NHL ) Unresponsive Rituximab Rituximab-Containing Regimen</brief_title>
	<detailed_description>Ofatumumab anti-CD20 monoclonal antibody show monotherapy activity patient follicular lymphoma relapse follow rituximab-containing therapy . Bendamustine approve FDA treatment patient indolent B-cell Non-Hodgkin 's Lymphoma ( NHL ) respond rituximab rituximab-containing regimen within 6 month last rituximab treatment . Biologics demonstrate enhanced efficacy add chemotherapeutic combination frontline treatment indolent NHL . The combination ofatumumab bendamustine may provide additional clinical benefit efficacy longer respond rituximab rituximab-containing regimen . The objective study determine effect ofatumumab bendamustine combination therapy patient indolent B-cell NHL respond rituximab rituximab-containing regimen within 6 month last rituximab treatment .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Indolent lymphoma include Grades 13a follicular , small lymphocytic , lymphoplasmacytic , marginal zone lymphoma ; Stages IIIIV , bulky disease , Stage II . Tumor verify CD20+ CT image do screen verify disease Indolent Bcell NHL remain stable unresponsive within 6 month treatment rituximab rituximabcontaining regimen Indolent lymphoma include grade 13a follicular , small lymphocytic , lymphoplasmacytic , marginal zone lymphoma ; stage IIIIV , bulky disease stage II ( i.e . single mass &gt; 5 cm direction ) ECOG Performance Status 0 , 1 , 2 Life expectancy least 6 month 18 year old Signed , write informed consent Grade 3b follicular lymphoma evidence indolent lymphoma transform aggressive lymphoma Previous allogeneic stem cell transplant Previous autologous stem cell transplant , fludarabine therapy , radioimmunotherapy past 12 month Previous external beam radiation therapy pelvis . Previous external beam radiation therapy bony disease cranium , mediastinum , axilla , two 3 vertebral body High dose steroid great equal 60 mg prednisone/day ( equivalent ) within 3 month randomization . No 10 mg prednisone ( equivalent ) daily time randomization Prior bendamustine treatment within 1 year randomization result CR PR least 6 month Treatment antiCD20 monoclonal antibody within 3 month randomization Known CNS involvement indolent lymphoma Other past current malignancy . Subjects free malignancy least 5 year history definitively treat nonmelanoma skin cancer , successfully treat situ carcinoma , eligible Chronic current active infectious disease require systemic antibiotic , antifungal , antiviral treatment Clinically significant cardiac disease History significant cerebrovascular disease event significant symptom Positive serology Hepatitis B Current active liver biliary disease ( except Gibler 's syndrome asymptomatic gallstone , liver metastasis , otherwise stable chronic liver disease ) Known HIV positive Abnormal/inadequate blood value , liver kidney function Current participation clinical study Inability comply protocol activity Lactating pregnant woman female patient childbearing potential ( male patient partner ) willing use adequate contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Refractory</keyword>
	<keyword>Safety</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Rituximab refractory</keyword>
	<keyword>Oncology</keyword>
</DOC>